Alternatives to MeMed

Develops a proprietary, stand-alone platform for rapid, lab-grade molecular diagnostics at the point of need.

Hacking healthcare with CRISPR technology.

Sight Diagnostics develops rapid, accurate, and convenient diagnostic testing solutions, including a complete blood count analyzer.

Visby Medical develops and manufactures instrument-free, PCR-quality rapid diagnostic tests for infectious diseases at the point of care.

EarliPoint Health develops a digital health platform for earlier identification and treatment of autism spectrum disorder (ASD) in children.

PixCell Medical develops and commercializes point-of-care blood diagnostic solutions for rapid and accurate results.

ImmunArray develops and markets novel multi-analyte blood-based tests for complex immune-mediated diseases using its iCHIP microarray platform.

Comprehensive whole-genome monitoring for cancer recurrence and progression.

Firefly Neuroscience provides objective brain function assessments for mental illness using FDA-cleared Brain Network Analytics (BNA™) technology.

Developing CORA, a smart exam for early detection of coronary artery disease.

Developing a liquid biopsy blood test for early disease detection and monitoring using epigenetic information.

MedHub-AI develops an AI-based decision support system for interventional cardiologists to enable precision cardiac care.

AI-powered diagnostic platform detecting and interpreting inaccessible body infra-sounds for enhanced medical diagnosis.

Developing novel diagnostics to predict patient response to immunotherapy.

AI-powered blood analysis for precise substance tracing and classification in healthcare and research.

Develops in-vitro diagnostic platforms for rapid antimicrobial susceptibility testing.

AI-powered blood test for early cancer detection and subtyping.

AI-driven diagnostics that convert medical images into actionable genomic insights for faster cancer treatment decisions.

Scopio Labs transforms cell morphology analysis with fully digital platforms and diagnostic support for faster, more accurate disease detection.

Pioneering volatile markers (VM) tests for early cancer detection in large-scale populations.